The Illnesses of Unknown Etiology section aims to provide a translational medicine forum for the publication of research on illnesses, multi-system diseases and syndromes of unknown etiology.
Edited by Monica C. Panelli, the section welcomes research on all aspects of ME/CFS and multi-system diseases of unknown cause with applications in medicine and biotechnology, as well as contributions that employ traditional clinical, metabolic, epidemiologic, genomics and proteomics methods as diagnostic and prognostic tools.
Read the latest articles in the Illnesses of Unknown Etiology section
Colorectal cancer (CRC) ranks third in incidence and second in mortality. In 2020, 1.9 million new cases were estimated and among them, a large population is diagnosed at an advanced stage; nevertheless, the efficacy of current therapies for late-stage CRC is limited. N6-methyladenosine (m6A) RNA methylation plays a critical role in key genetic events for various cancers; yet, how m6A functions within the tumor microenvironment (TME) remains to be elucidated.
In this article, researchers investigated the influence of m6A mRNA methylation on the main TME cells. It reveals, for the first time, that m6A mRNA may guide intercellular communication of TME cells with tumor cells to contribute to colorectal cancer progression.
Chimeric antigen receptor (CAR) T cell therapy has attracted attention for its promising therapeutic effects on hematological malignancies. However, there are problems such as relapse during long-term follow-up and limited effect on solid tumors with this therapy. Exhaustion, which impairs in vivo persistence and killing activity of CAR T cells, is one of the causes of these issues. Depending on their structure of extracellular portion, some CARs induce tonic signals in the absence of ligand stimulation and induce exhaustion phenotype in CAR T cells.
In this review, Kouro and colleagues introduced examples of self-activating CARs and summarized their phenotypes to investigate how CAR T cell exhaustion occurs.
Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.
Read MoreGet to know the Editors behind Journal of Translational Medicine!
Please note that Journal of Translational Medicine is no longer considering submissions of study protocols.
Causal relationship between physical activity, leisure sedentary behaviors and COVID-19 risk
Improving public cancer care by implementing precision medicine in Norway
Check out last month's top 20 most discussed articles from Journal of Translational Medicine!
nadia_buravleva / stock.adobe.com
Journal of Translational Medicine would like to warmly thank the top reviewers whose comments helped to shape the journal, for their assistance with review of manuscripts in Volume 18 (2020).
Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine.
The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.
Led by Section Editor Marcello Maggiolini, this exciting new section is dedicated to uncovering pivotal transduction signaling involved in pathophysiological processes toward a translational impact on the discovery of novel targets and therapeutics.
Translational Signaling and System Biology section welcomes articles providing new mechanistic insights on a broad range of fields, drug action through new formulations and delivery methods, novel cellular and animal models, computational and systems biology, and innovative laboratory concepts fostering translational research from the bench to the bedside.
Led by Section Editor Giuseppe Intini, this new section aims to foster new discoveries in the field of Craniofacial and Dental Medicine. It is interested in interested in research that investigates innovative approaches in all craniofacial and dental specialties, including oral medicine and oral pathology.
Translational Craniofacial and Dental Medicine will consider studies regarding therapeutic approaches for treatment of diseases and for tissue regeneration, biomaterials for restorative prosthesis and implantology, diagnostic tools, imaging, and large data analysis. Translational genomics and precision medicine studies that identify novel prognostic markers, tailored interventions, and prophylactic approaches are also welcome.
Led by Section Editor Claire Vanpouille-Box, this new section is interested in innovative research that investigate the crosstalk between ionizing radiations (IR), the tumor microenvironment (TME) and host immunity.
Studies considered for publication include (but not limited to) those investigating the mechanisms of radiation-induced anti-tumor immune responses, the immune-stimulatory and immuno-suppressive properties of ionizing radiation from all sources, biomarkers predictive of immune response, immune escape mechanisms elicited by IR and radioresistance. Importantly, the section welcomes translational and clinical studies assessing the combination of IR with immunotherapies (IT) with an emphasis on clinical response and outcome.
Led by Section Editor Gennaro Ciliberto, this exciting section is dedicated to the wave of emerging therapeutics arising from the intense research efforts and therapeutic breakthroughs based on recent scientific and technological developments.
Emerging Therapeutics is interested in original papers, reviews and perspectives on the advancements in the field, including genetic vaccines, monoclonal antibodies, CAR-Ts, gene therapy with viral vectors, clinical applications of CRISPR/CAS9 gene editing, microbiota-modulating approaches, ‘omics approaches, emerging therapeutics from the development of new technologies for drug development, and discovery of new intervention targets and the possibility for new drug combinations.
Dr. Marincola received his MD, summa cum laude from the University of Milan, Italy and Surgery training at Stanford University, California. His research interest lies in translational medicine and focuses on the development of strategies for the dynamic study of patients’ response to immunotherapy. His approach has brought seminal observations regarding the mechanisms leading to rejection of tumors, allograft rejection, graft-versus-host disease and autoimmunity.
Dr. Marincola is currently Global Head of Research at Kite Pharma, Santa Monica, California. He previously was President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation in Redwood City, California, Chief Research Officer at Sidra Medical and Research Center in Doha Qatar and Tenured Investigator at the National Institutes of Health, Bethesda Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine of which he is currently the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and of the International Society for Translational Medicine. Dr. Marincola is editor of several biomedical books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning fiction writer author of The Wise Men of Pizzo and the Cat Behind the Window.
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.
The journal covers all areas of translational medicine but also has several special sections:
Citation Impact
5.531 - 2-year Impact Factor
5.760 - 5-year Impact Factor
1.244 - Source Normalized Impact per Paper (SNIP)
1.576 - SCImago Journal Rank (SJR)
Speed
8 days to first decision for all manuscripts
60 days to first decision for reviewed manuscripts only
115 days from submission to acceptance
13 days from acceptance to publication
Usage
4,155,992 Downloads (2021)
3,471 mentions